Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
|
|
- Claire Garrison
- 5 years ago
- Views:
Transcription
1 Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
2 Conflicts of Interest Lecture and Consultant Fees Abbott Astra Zeneca Biosensors Boston Scientific Cordis Edwards Lifesciences Eli Lilly Medtronic Sanofi Aventis
3 Target Lesion Revascularization Network Meta-Analysis: DES vs BMS Stettler C et al. Brit Med J 28 Diabetic Patients N=3,853 Non-Diabetic Patients N=1,947
4 Benefit of Drug-Eluting Stents in Diabetic and Non-Diabetic Patients NNT for Diabetic 4 Years NNT=5 CI 5-6 NNT=7 CI 5-8 NNT for Non-Diabetic 4 Years NNT=7 CI 7-8 NNT=1 CI 8-13 SES vs BMS PES vs BMS SES vs BMS PES vs BMS
5 Mortality in Trials With Clopidogrel for >6 Months Network Meta-Analysis of DES vs BMS Stettler C et al. Brit Med J 28 Diabetic Patients N=3,853 Non-Diabetic Patients N=1,947
6 Overall Mortality in Diabetic Patients Meta-Analysis of 3,853 Diabetic Patients Stettler C et al. Brit Med J 28 Impact of Dual Antiplatelet Therapy Duration SES vs. BMS PES vs. BMS Clopidogrel <6 months Clopidogrel >6 months HR=2.37 ( ) HR=.89 ( ) Clopidogrel >6 months HR=.97 ( ) P value for interaction =.2
7 Differential Benefit of Gp IIb/IIIa-Inhibitors in ACS Patients in Relation to Diabetes Roffi et al. Circulation 21;14: day Mortality Trial N Odds Ratio & 95% CI Placebo IIb/IIIa PURSUIT % 2.4% p =.57 PRISM %.% p =.5 PRISM-PLUS 17 p = %.% GUSTO IV 239 p = % 1.2% PARAGON A 45 p = %.% PARAGON B 284 p =.6 4.3%.7% p =.2 Pooled % 1.2% NNT = 36 IIb/IIIa Better Placebo Better
8 Triton TIMI 38 Prasugrel vs. Clopidogrel by Diabetes Status: Primary End Point Wiviott SD et al. Circulation 28;118: Primary End Point (%) Diabetes Mellitus Days No Diabetes Mellitus HR.7 ( ), P<.1 HR.86 ( ), P =.2 18 Clopidogrel Prasugrel 12.2 P interaction = Days Clopidogrel 1.6 Prasugrel 9.2
9 Triton TIMI 38 Prasugrel vs. Clopidogrel Wiviott SD et al. Circulation 28;118: Non-CABG TIMI Major Bleeding 5 Diabetes Mellitus No Diabetes Mellitus HR 1.6 ( ), P =.81 HR 1.43 ( ), P =.2 5 TIMI Major Bleeding (%) Clopidogrel 2.6 Prasugrel Clopidogrel 2.4 Prasugrel Days P Days interaction =.29
10 ESC 21 Guidelines for Revascularization Compared with BMS, DES reduce the need for repeat TVR in diabetic patients (I A).
11 Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention STEMI NSTE-ACS Chronic stable angina
12 Advances in Cardiac Care in Diabetic Patients With STEMI Sobel B et al. Coronary Artery Disease 21;21: Defibrillation Monitoring Beta-Blockade 28 Aspirin Thrombolysis 12 PCI Thienopyridines 7,5 Pre-CCU era CCU era Fibrinolysis Primary PCI
13 Diabetes and Mortality in Acute STEMI GUSTO-I Thrombolysis Trial Mortality (%) (%) % % Diabetes No Diabetes Days K-H Mak et al. JACC 1997;3:171-9
14 Acute Myocardial Infarction Thrombolysis vs. Primary PCI: Short-Term Results Keeley EC et al. Lancet 23;361: P< lives and 44 MI`s saved and 11 strokes avoided for every 1 pts treated with primary PCI instead of thrombolysis 43% Death, MI, Stroke 22% 57% P= P< Meta-Analysis -N=7739 patients -23 randomized trials -8x:streptokinase vs PTCA -15x: tpa vs PTCA 5% P< % P<.1.5 Death Reinfarction Stroke ICH 1 PCI Thrombolysis
15 Acute ST-Elevation Myocardial Infarction Primary PCI versus Thrombolysis in Diabetics Timmer JR et al. Arch Intern Med 27;167: % 15 1 Diabetic Patients 3 Days OR=.49 95% CI P=.4 NNT= % 15 1 Non-Diabetic Patients 3 Days OR=.69 95% CI P=.1 NNT= Primary PCI Thrombolysis Primary PCI Thrombolysis 19 RCTs comparing PPCI and Thrombolysis in 6,315 patients
16 Prehospital Thrombolysis vs Primary PCI in STEMI Bonnefoy E et al. Eur Heart J 25;26: Outcome in Diabetic 3 Days CAPTIM Trial 25 2 P=.9 P=.29 P=.69 P= % ,8 Death, MI or Stroke 13 5,3 5,5 7,5 2,5 Death MI Stroke Primary PCI Fibrinolysis N=57 N=46
17 Mortality in Cardiogenic Shock Complicating Acute Myocardial Infarction Shindler M et al. J Am Coll Cardiol 2;36: Hochman J et al. JAMA 26;295: Long-term Outcome Month Mortality HR=.71 ( ) 45 HR=.8 ( ) Diabetes No Diabetes Revacularization Medical Theray
18 ESC 28 Recommendations for STEMI ESC 21 Guidelines for Revascularization Reperfusion therapy is indicated in all patients with history of chest pain of <12 h and with persistent ST-elevation or new LBBB (I A). Mechanical reperfusion by means of primary PCI is the revascularization mode of choice in diabetic patients with AMI. (I-A).
19 Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention STEMI NSTE-ACS Chronic stable angina
20 Diabetes and Acute Coronary Syndromes Impact on Mortality PARAGON A PARAGON B PURSUIT GUSTO IV Diabetes Independent Predictor of Mortality HR 1.7 Diabetes, N = 5,49 No Diabetes, N = 19, Days 5.5% 3.% p <.1
21 Acute Coronary Syndromes Routine Invasive Versus Conservative Strategy Anderson et al. J Am Coll Cardiol 27;5:e1-157 Death Recurrent MI OR=.75 (.63-.9) OR=.83 ( )
22 Primary Endpoint at 6 Months (%) Invasive Conservative NSTE ACS Invasive vs. Conservative Strategy Impact of Diabetes Mellitus Norhammar A et al. JACC 24;43: Roffi et al. Eur Heart J 24;25:19-8 FRISC II TACTICS-TIMI % % No Diabetes Diabetes No Diabetes Diabetes
23 Acute Coronary Syndromes PCI vs CABG in Diabetic Patients - AWESOME Sedlis SP et al. J Am Coll Cardiol 22;4: Mortality Through 5 Years -Period patients with unstable angina and at least one high risk feature (previous CABG, MI, LVEF<35%, >7 YO, IABP) -randomized to PCI or CABG -32% diabetic patients
24 Invasive Procedures in the CRUSADE Registry Brogan GX et al. Diabetes Care 26;29:^9-14 Catheterization Procedures in Patients With NSTE ACS % ,4 No DM vs NIDDM OR=1.5 95% CI ,6 No DM vs IDDM OR=.94 95% CI ,3 No Diabetes NIDDM IDDM N=31,49 N=9,773 N=5,588
25 ESC 27 Recommendations for Diabetes An early invasive strategy is recommended for diabetic patients with NSTE-ACS (I A). Diabetic patients with NSTE-ACS should receive intravenous GP IIb/IIIa inhibitors as part of the initial medical management which should be contined through the completion of PCI (IIa-B).
26 Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention STEMI NSTE-ACS Chronic stable angina
27 Diabetes and Revascularization Results from the Euro-Heart Survey Anselmino et al. Eur J Cardiovasc Prev Rehabil 28;15: Freedom from MACE No DM, Revasc No DM, No Revasc DM, Revasc Multivariable Regression HR.61 95% CI P=.25 DM, No Revasc 3,488 patients included at 11 centers in 25 European countries
28 Impact of Revascularization on Mortality in Diabetic Patients With Multivessel Disease Soares PR et al. Circulation 26;114:I-42-4 MASS II trial: 611 patients with multivessel disease randomly assigned to medical treatment, PCI or CABG Diabetic Patients Non-Diabetic Patients 2-5 years P= years P=.5
29 Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease BARI 2D Study Group. N Engl J Med 29;36: centers -Enrollment 21 to 25 -Inclusion based on coronary angiography stenosis >5% -Exclusion: immediate revascularization required, LM disease -Randomization: medical therapy vs revascularization -Revascularization method: determined by treating physician Enrollment target of 2,8 patients not met; follow-up extended by 1.5 years
30 1 Endpoint: Death MACE: Death, MI, CVA Peri-procedural MI: PCI CK-MB >3xULN CABG CK-MB >1xULN Power: 88% to detect a 3% reduction in death (14% 9.5%) Complete follow-up 93% PCI=798 pts CABG=378 pts
31 Revascularization Procedures in BARI-2D BARI 2D Study Group. N Engl J Med 29;36: Cumulative Rate of First Revascularization Procedure
32 BARI 2D vs Euro Heart Survey-DM Mortality BARI 2 D 12% at 5 years (2.4%/year) Euro Heart Survey 7.6% at 1 year ~3x Mortality MACE (death, MI, stroke) BARI 2D 24% et 5 years (2.8%/year) Euro Heart Survey 14.5% at 1 year ~4x MACE
33 Revascularization in Multivessel CAD PCI versus CABG PCI -less invasive -shorter hospitalisation -lower risk of CVA -quality of life CABG -more complete revascularization -fewer repeat revascularizations -protection against future events Gersh et al. NEJM 25
34 Meta-Analysis: CABG versus PCI Hlatky M et al. Lancet 29;373:119-7 Impact of Diabetes on Overall Mortality % 4 HR=.7 ( ) HR=.98 ( ) Diabetics (N=1233) CABG Non-Diabetics (N=6561) PCI
35 CARDIA CABG vs PCI in Diabetic Patients Kapur A et al. J Am Coll Cardiol 21;55:432-4 Clinical Outcome at 12 Months Death, MI, Stroke Death Revascularization % P= ,5 13 % P=.97 % ,8 P< ,2 3, PCI (N=254) CABG (N=248) PCI (N=254) CABG (N=248) PCI (N=254) CABG (N=248)
36 Mortality (% ) Mortality (% ) Mortality According to SYNTAX Score Banning A et al. J Am Coll Cardiol 21;55: CABG TAXUS Stent Non-Diabetic Diabetic 2 P=.26 P=.48 P=.4 2 P=.51 P>.99 P= SYNTAX Score -22 (n=437) (n=454) 33 (n=449) -22 (n=136) (n=156) 33 (n=157)
37 Adverse Cerebral Outcomes After Coronary Artery Bypass Surgery Roach et al. N Engl J Med 1996;335: Type I neurologic deficit: stroke, TIA, coma Type II neurologic deficit: deterioration of intellect or seizures Type I (Overall: 3.1%) 8 Type II (Overall: 3.%) < >8 (years)
38 Risk of Stroke in Diabetic Patients - CABG vs PCI SYNTAX Banning JACC 21 CARDIA Kapur JACC 21 % 3 2 No Diabetes Diabetes Diabetes % P=.6 3 P=.26 2,2 2,5 2 2 % 3 P=.7 2,8 1,6 1,9 1,4 PCI (N=672) CABG (N=676) PCI (N=231) CABG (N=221) PCI (N=254) CABG (N=248)
39 Antiatherosclerosis Therapy in Diabetic Patients Beckman JA et al. JAMA 22;287:257-81
40 CABG versus PCI in Diabetic Patients Diabetes increases mortality with both CABG and PCI CABG and PCI have similar safety profile (death/mi/cav) in diabetic and non-diabetic patients with low and medium complexity (SYNTAX score<33) CABG is therapy of choice for diabetic and nondiabetic patients with SYNTAX scores 33 due to higher mortality with PCI Threshold for surgery should be lower in diabetic patients than in non-diabetic counterparts (especially in IDDM) Increased risk of stroke with CABG Cave: elderly patients (>75 YO)
Management of cardiovascular disease - coronary interventions -
Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationMaster Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationACUTE CORONARY SYNDROME PCI IN THE ELDERLY
ACUTE CORONARY SYNDROME PCI IN THE ELDERLY G.KARABELA MD.PhD ATHENS NAVAL HOSPITAL INTERVENTIONAL CARDIOLOGY DEPARTMENT NO CONFLICT OF INTEREST TO DECLAIRE Risk stratification in Αcute Coronary Syndrome.
More informationIssues in the Management of Diabetic Patients with Cardiovascular Disease
Issues in the Management of Diabetic Patients with Cardiovascular Disease Elliot Rapaport, MD December 13, 2008 1 Hyperglycemia and Acute Coronary Syndromes 2 Effect of Hyperglycemia in STEMI Impairs microvascular
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationPharmaco-Invasive Approach for STEMI
Pharmaco-Invasive Approach for STEMI Michael C. Kontos, MD Medical Director, Coronary Intensive Care Unit Director, Chest Pain Evaluation Center Associate Professor Departments of Internal Medicine (Cardiology),
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationPatient Transfer. Mark de Belder The James Cook University Hospital Middlesbrough
Patient Transfer Mark de Belder The James Cook University Hospital Middlesbrough Current Management Strategies for ACS ACS No ST Elevation ST ST Elevation Elevation Early Invasive Early Conservative Fibrinolysis
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationWhat is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN
What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN October 2011 Part 2 Summary of newer antithrombotic and antiplatelet agents in STEMI Role of thrombectomy in PPCI
More informationSHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?
SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationSpeaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationThe Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium
The Window for Fibrinolysis Frans Van de Werf, MD, PhD Leuven, Belgium ESC STEMI Guidelines : December 2008 Reperfusion Therapy: Fibrinolytic Therapy Recommendations Class LOE In the absence of contraindications
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationLeft Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
More informationAkute Koronarsyndrome
12. Berner Notfall-Symposium, 17. Oktober 2013 Akute Koronarsyndrome Risikostratifizierung, Netzwerkstrategie und Medikamenten-Update Stephan Windecker Department of Cardiology Swiss Cardiovascular Center
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationThe Strategic Reperfusion Early After STEMI study Implications for clinical practice
The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationDecision for fibrinolysis or primary PCI in the prehospital phase
Decision for fibrinolysis or primary PCI in the prehospital phase Nicolas Danchin, Hôpital Européen Georges Pompidou, Paris, France Disclosures Research grants: Astrazeneca, Eli-Lilly, GSK, Merck, Novartis,
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationRecognizing the High Risk NSTEMI Patient for Early Appropriate Therapy
Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More informationUpstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia
Upstream P2Y 12 RB Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia Dio può essere dimostrato Le dimostrazioni dell esistenza di Dio IA Dio non può essere dimostrato
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationMedical Rx vs PCI vs CABG
Medical Rx vs PCI vs CABG S. Hinan Ahmed, MD Associate Professor: Cardiology and Cardiothoracic Surgery Program Director: Interventional Fellowship Program Assoc Editor: Cath and Cardiovasc Intervention
More informationSHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?
SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationGeriatric Grand Rounds. Geriatric Grand Rounds. Heart Disease in the Elderly: Pitfalls and Practicalities. Objectives. Conflict of Interest Disclosure
Geriatric Grand Rounds Tuesday, January 22, 2008 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital To receive the poster, and handouts via email, subscribe to our E-mailing list at
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationUpdate on the management of STEMI. Elliot Rapaport, M.D. San Francisco, CA December 14, 2007
Update on the management of STEMI Elliot Rapaport, M.D. San Francisco, CA December 14, 2007 Universal MI Definition Committee 2007 Recommendations Type 1 Spontaneous MI associated with ischemia and due
More informationIschemic and bleeding risk stratification in NSTE ACS. Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland
Ischemic and bleeding risk stratification in NSTE ACS Andrzej Budaj Postgraduate Medical School Grochowski Hospital, Warsaw, Poland Disclosure Andrzej Budaj, MD, PhD, reports the following potential conflicts
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationSTREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve
STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION PCI Hospital Ambulance/ER STREAM design STEMI
More informationCritics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS
Critics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS STEMI Stuff New or Recurrent MI s in U.S.: 865,000 Acute STEMI s: 500,000 Sooner
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationHow to manage ACS patients with Comorbidities? Patients with Renal Failure
How to manage ACS patients with Comorbidities? Patients with Renal Failure François Schiele, MD, PhD Department of Cardiology, University Hospital Jean Minjoz, Besançon, France. Potential conflicts of
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More information2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More informationManagement of STEMI in era of Reperfusion. Eagles Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police
Management of STEMI in era of Reperfusion Eagles 2007 Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police STEMI in US ST Segment Elevation Myocardial Infarction (STEMI) ~500 K per year Thrombolysis
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngioplastica coronarica nel paziente anziano ad alto rischio emorragico
Attualità in Cardiologia Aprilia, Enea Hotel 22 ottobre 2011 Angioplastica coronarica nel paziente anziano ad alto rischio emorragico Fabrizio Tomai, MD, FACC, FESC Dept. of Cardiovascular Sciences - Interventional
More informationSTEMI Care 2014 at the Crossroads: Taking the right road
STEMI Care 2014 at the Crossroads: Taking the right road Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Vice President, The Canadian Association of Interventional Cardiology Director,
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationPathophysiology of ACS
Pathophysiology of ACS ~ 2.0 MM patients admitted to CCU or telemetry annually 0.6 MM ST-segment elevation MI 1.4 MM Non-ST-segment elevation ACS NSTEMI vs STEMI VANQWISH Boden et al N Engl J Med 1998;338:1785-1792
More informationPrimary Percutaneous Coronary Intervention
The big 5 in PCI Primary Percutaneous Coronary Intervention W. Wijns (Aalst, BE) Disclosures Consulting Fees: on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationStent Thrombosis Importance of Pharmacotherapy
Stent Thrombosis Importance of Pharmacotherapy George D. Dangas, MD, FSCAI Columbia University Medical Center Cardiovascular Research Foundation New York City SCAI-2007 Orlando, FL Presenter Disclosure
More informationCOPYRIGHT. Harvard Medical School
Agenda New Rapid Rule Out Strategy General Guidelines and Therapies Assessing Patient Risk Timing of Catheterization Navigating Anticoagulant/Antiplatelet Choices Newer Choices and new data The Future
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationThe Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why.
Implementing the pharmacoinvasive strategy in STEMI The Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why. 7:20-7:40 Robert C. Welsh, MD, FRCPC, FESC, FAHA, FACC Professor of Medicine Director,
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More information